Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Redefining clinical success in minimally invasive surgery for BPH: A composite endpoint integrating ejaculatory function, urinary improvement, and safety metrics.

Urologia·2026
Same author

Corrigendum to "Systematic review and pooled analysis of functional and sexual outcomes of minimally invasive surgical treatments for benign prostatic obstruction" [Eur. Urol. 89 (2026) 318-331].

European urology·2026
Same author

Too late to fall: Time to PSA nadir and early oncologic failure after cryotherapy and high-intensity focused ultrasound for localized prostate cancer.

Current problems in cancer·2026
Same author

Sutureless Purely Off-clamp Robotic Partial Nephrectomy: Evidence from a Randomized Controlled Noninferiority Trial.

European urology·2026
Same author

Learning Curve of Docking Time in Robot-Assisted Radical Prostatectomy with the Hugo RAS System: How Many Procedures to Achieve Efficiency?

Journal of clinical medicine·2026
Same author

Single-port versus multi-port robotic radical prostatectomy: a within-surgeon, propensity-matched analysis of platform-related effects.

Journal of robotic surgery·2026

Related Experiment Video

Updated: May 31, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Preoperative Risk Stratification Approach Using the Focal Risk Group (FRG) in Patients Undergoing Focal Therapy for

Umberto Anceschi1, Salvatore Basile1, Riccardo Mastroianni1

  • 1Department of Urology, Uro-Oncology Program, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Clinical Genitourinary Cancer
|May 28, 2026
PubMed
Summary
This summary is machine-generated.

A new Focal Risk Group (FRG) classification helps predict biochemical failure risk in localized prostate cancer patients undergoing focal therapy. This tool aids in understanding baseline risk before treatment.

Keywords:
Biochemical recurrenceGradingPreoperative classification

More Related Videos

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Related Experiment Videos

Last Updated: May 31, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Area of Science:

  • Urology
  • Oncology
  • Medical Informatics

Background:

  • Preoperative risk stratification for localized prostate cancer treated with focal therapy is not well-defined.
  • A novel classification system, the Focal Risk Group (FRG), was developed using readily available clinical variables.
  • The FRG aims to describe the baseline risk of biochemical failure following focal therapy.

Purpose of the Study:

  • To develop and validate a simple, clinically informed classification system for risk stratification in patients undergoing focal therapy for prostate cancer.
  • To assess the association of the FRG with biochemical failure-free survival (BFS) after focal therapy.
  • To evaluate the discriminative ability of the FRG in predicting treatment outcomes.

Main Methods:

  • Analysis of 324 patients treated with cryoablation or high-intensity focused ultrasound.
  • Development of the FRG incorporating PSA density, ISUP grade group, dominant lesion size, and clinical stage.
  • Utilized Cox regression, Kaplan-Meier analysis, and AUC to assess BFS and discrimination.

Main Results:

  • The FRG successfully stratified patients into low, intermediate, and high-risk groups with significantly different BFS rates (log-rank P = .0013).
  • 24-month BFS rates were 84.8% (low), 71.8% (intermediate), and 59.9% (high risk).
  • Dominant lesion size was independently associated with BFS (HR 1.03, P = .02), and overall discrimination was modest (AUC 0.66).

Conclusions:

  • The developed Focal Risk Group (FRG) classification is associated with biochemical failure after focal prostate cancer therapy.
  • The FRG may assist in describing patient baseline risk prior to focal therapy.
  • External validation and cautious interpretation are recommended due to the exploratory nature and modest discrimination of the FRG.